SCHEMBL30101255

SCHEMBL30101255

CC1CCC(OC(=O)c2ccccc2)CO1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
CHRNA7 P36544 4/20 0.51
HTR3E A5X5Y0 1/20 0.51
HTR3B O95264 1/20 0.51
HTR3A P46098 1/20 0.51
HTR3D Q70Z44 1/20 0.51
HTR3C Q8WXA8 1/20 0.51
APOBEC3A P31941 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
GAA P10253 1/20 0.49
BCHE P06276 1/20 0.47
SCN1A P35498 1/20 0.46
SCN2A Q99250 1/20 0.46
SCN3A Q9NY46 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.45
CARM1 Q86X55 1/20 0.45
PRMT6 Q96LA8 1/20 0.45
LMNA P02545 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL469812 1.00 MEN1 (0.52) MEN1KMT2ACHRNA7HTR3EHTR3B
SCHEMBL31113478 0.85 PTPN2 (0.57) MEN1KMT2ASCN1ASCN2ASCN3A
SCHEMBL32678657 0.84 BCHE (0.46) BCHE
SCHEMBL32678656 0.84 BCHE (0.46) BCHE
SCHEMBL31113601 0.84 ALDH1A1 (0.49) KMT2AGAABCHELMNATDP1
SCHEMBL11636361 0.83 MEN1 (0.53) MEN1KMT2ACHRNA7HTR3EHTR3B
SCHEMBL4453290 0.80 MEN1 (0.69) MEN1KMT2ACHRNA7HTR3EHTR3B
SCHEMBL1786140 0.80 MEN1 (0.69) MEN1KMT2ACHRNA7HTR3EHTR3B
SCHEMBL1564914 0.79 CHRNA7 (0.48) MEN1KMT2ACHRNA7HTR3EHTR3B
SCHEMBL29949611 0.79 CHRNA7 (0.48) MEN1KMT2ACHRNA7HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4683641-A1 AZITHROMYCIN DERIVATIVES FOR USE IN THE TREATMENT OF EOSINOPHIL-RELATED DISEASES EpiEndo Pharmaceuticals ehf. (IS) 2026-01-28 EP claimed
WO-2024194494-A1 AZITHROMYCIN DERIVATIVES FOR USE IN THE TREATMENT OF EOSINOPHIL-RELATED DISEASES EPIENDO PHARMACEUTICALS EHF (IS) 2024-09-26 WO claimed
WO-2026041802-A1 AZITHROMYCIN DERIVATIVES FOR USE IN THE TREATMENT OF INFECTIONS EPIENDO PHARMACEUTICALS EHF (IS) 2026-02-26 WO disclosed
EP-4683641-A1 AZITHROMYCIN DERIVATIVES FOR USE IN THE TREATMENT OF EOSINOPHIL-RELATED DISEASES EpiEndo Pharmaceuticals ehf. (IS) 2026-01-28 EP disclosed
CN-120152721-A Treatment of familial adenomatous polyposis with 13-membered macrolides 齐卡尼治疗股份有限公司 2025-06-13 CN disclosed
CN-119731188-A Synthetic methods and intermediates for preparing therapeutic azaketolides 齐卡尼治疗股份有限公司 2025-03-28 CN disclosed
WO-2024194494-A1 AZITHROMYCIN DERIVATIVES FOR USE IN THE TREATMENT OF EOSINOPHIL-RELATED DISEASES EPIENDO PHARMACEUTICALS EHF (IS) 2024-09-26 WO disclosed
EP-4358970-A1 COMPOUNDS FOR TREATING GENETIC DISEASES Zikani Therapeutics, Inc. (US) 2024-05-01 EP disclosed
WO-2023250513-A1 13-MEMBERED MACROLIDE COMPOUNDS FOR TREATING DISEASES MEDIATED BY ABNORMAL PROTEIN TRANSLATION ZIKANI THERAPEUTICS, INC. (US) 2023-12-28 WO disclosed
WO-2023235380-A1 MACROLIDES FOR TREATING GENETIC DISEASES ZIKANI THERAPEUTICS, INC. (US) 2023-12-07 WO disclosed
WO-2022251730-A1 COMPOUNDS FOR TREATING GENETIC DISEASES ZIKANI THERAPEUTICS, INC. (US) 2022-12-01 WO disclosed